Until this year, there were no effective treatments for chronic kidney disease. However, the recent approval of AstraZeneca’s Farxiga alongside clinical breakthroughs and advances in precision medicine are causing the field to resurge.
The last several months have seen big pharma companies scoring wins against chronic kidney disease (CKD). This condition involves gradual, irreversible kidney damage and often overlaps with common age-related ailments such as cardiovascular disease and diabetes.
AstraZeneca led the way in April with the FDA approval of Farxiga. Farxiga became the first approved drug to slow the progression of CKD arising from multiple causes; there are already drugs in the market for a form of CKD in diabetes sufferers, such as Johnson and Johnson’s Invokana. Farxiga, which was first approved by the EU to treat diabetes in 2012, works by lowering harmful blood sugar levels and blood pressure in the kidney blood vessels.
Last month, an antibody drug developed by Novo Nordisk reduced signs of atherosclerosis in CKD patients in phase II. And Bayer’s drug finerenone lowered the risk of cardiovascular events like heart attacks and strokes in a phase III study in patients with CKD and type 2 diabetes.
The post Farxiga’s Approval Fuels Chronic Kidney Disease Comeback appeared first on Labiotech.eu.
Published on Tue, 08 Jun 2021 15:51:45 +0000 with keywords Apptigent PowerTools